Esketamine, a drug that has been used as a “recreational party drug,” is being marketed as Spravato by Janssen Pharmaceuticals who claim it is effective for “treatment-resistant depression.” European drug regulators, NICE, recently announced it does not recommend Janssen’s product citing “concerns over the effect of stopping esketamine treatment, whether symptom improvements will continue and if these can improve someone’s quality of life.”

Read the full story here.